RePORT Indonesia is part of the ongoing government-to-government partnership between the National Institutes of Allergy and Infectious Diseases (NIAID), and Indonesia National Institute of Health Research and Development (NIHRD), Ministry of Health (MOH), Indonesia. Indonesia is collaborating with RePORT International through the Indonesia Research Partnership on Infectious Disease (INA-RESPOND) project, funded by the U.S. NIH/NIAID and the Indonesia MOH/NIHRD. This existing partnership between the two governments supports a network of nine academic and research institutions and hospitals to conduct research on infectious diseases and is currently conducting research on febrile illness in Indonesia.  The Indonesian MOH has identified TB as a national priority disease area.


The Indonesia network has developed a study that will enroll 1,000 presumptive new TB cases and 357 previously treated cases. Like RePORT Brazil, the parent study has been harmonized with the RePORT International Common Protocol for collecting data and biospecimens using standardized methods and agreed upon time points.  Drug susceptible and multi-drug resistant (MDR) patients will be followed from commencement to end of treatment for drug sensitive patients and two years for MDR patients. Indonesia is considering expanding the study to include household contacts of active cases.  The first site (Sanglah Hospital) was approved on January 26, 2017 and began screening patients on February 7, 2017. There are now four sites activated, and as of June 2017, 40 subjects enrolled.